Thyroid Gland Undifferentiated (Anaplastic) Carcinoma
Conditions
Brief summary
This phase II trial studies how well pembrolizumab, chemotherapy, and radiation therapy work with or without surgery in treating patients with anaplastic thyroid cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as docetaxel and doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving pembrolizumab, chemotherapy, and radiation therapy with or without surgery may kill more tumor cells and work better in treating patients with anaplastic thyroid cancer.
Detailed description
PRIMARY OBJECTIVES: I. To assess the efficacy of pembrolizumab in improving overall survival at 6 months (OS-6) in combination with multimodal therapy involving standard chemo-radiotherapy in anaplastic thyroid cancer (ATC) in comparison to a historical cohort. SECONDARY OBJECTIVES: I. To determine safety and tolerance of pembrolizumab with chemoradiotherapy. TERTIARY OBJECTIVES: I. To evaluate locoregional control. II. To evaluate progression of distant metastases. III. To evaluate the evolution of the immune profile of circulating immune cells in response to therapy in ATC patents, and to assess potential correlations with outcomes on an exploratory basis. IV. To evaluate PD-1 and PD-L1 staining in tumor cells and tumor stroma as candidate biomarkers for outcomes. V. To determine if pre-therapy circulating tumor cell load is associated with outcomes. VI. To examine associations between outcomes and somatic mutational status as assessed by foundation medicine analysis (for example: presence of BRAF, RAS, P53 and TERT promoter mutations). OUTLINE: Patients are assigned to 1 of 2 cohorts. COHORT A: Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 17 courses after chemoradiation if no residual disease is found or for up to 35 courses after chemoradiation if residual disease is found. After 3 days, patients undergo surgery. Within 42 days of surgery, patients also receive docetaxel IV over 1 hour once weekly (Q1W) and doxorubicin hydrochloride IV Q1W, and undergo intensity-modulated radiation therapy (IMRT) once daily 5 days per week for 6.5 weeks in the absence of disease progression or unacceptable toxicity. COHORT B: Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 17 courses after chemoradiation if no residual disease is found or for up to 35 courses after chemoradiation if residual disease is found. After 3 days, patients also receive docetaxel IV over 1 hour Q1W and doxorubicin hydrochloride IV Q1W, and undergo IMRT once daily 5 days per week for 6.5 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months until progressive disease and then every 6 months for up to 5 years.
Interventions
DRUGDocetaxel
Given IV
DRUGDoxorubicin Hydrochloride
Given IV
RADIATIONIntensity-Modulated Radiation Therapy
Undergo IMRT
OTHERLaboratory Biomarker Analysis
Correlative studies
BIOLOGICALPembrolizumab
Given IV
PROCEDURETherapeutic Conventional Surgery
Undergo surgery
Sponsors
National Cancer Institute (NCI)
Mayo Clinic
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histological confirmation of, or cytology reported and confirmed, anaplastic thyroid cancer * NOTE: A diagnosis reported as ?poorly differentiated carcinoma consistent with anaplastic thyroid cancer? will be accepted * Absence of prior neck radiotherapy * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1 * Hemoglobin \>= 9.0 g/dL * White blood cells (WBC)/leukocytes \>= 3500/mm\^3 * Absolute neutrophil count (ANC) \>= 1500/mm\^3 * Platelet count \>= 100,000/mm\^3 * Total bilirubin =\< 1.5 x upper limit of normal (ULN) (except for patients with well-documented Gilbert?s syndrome) * Aspartate transaminase (AST) =\< 3 x ULN * Creatinine =\< 1.5 x ULN OR calculated creatinine clearance \>= 50 ml/min using the Cockcroft-Gault formula * Prothrombin time (PT)/activated partial thromboplastin time (PTT) =\< 1.5 x ULN, unless subject is receiving anticoagulant therapy and PT or activated (a)PTT is within therapeutic range of intended use of anticoagulants * Negative pregnancy test done =\< 7 days prior to registration, for persons of childbearing potential only * NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required * NOTE: Merck requires an additional pregnancy test if eligibility pregnancy test is \> 72 hours prior to first dose * Persons of childbearing potential must be willing to use an adequate method of birth control for the course of the study through 120 days after the last dose of study medication * NOTE: Abstinence is acceptable if this is the usual lifestyle and preferred method of contraception for the patient * Persons able to father a child must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy * NOTE: Abstinence is acceptable if this is the usual lifestyle and preferred method of contraception for the patient * Provide written informed consent * Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study) * Willing to provide tissue and blood samples for correlative research purposes
Exclusion criteria
* History of non-infectious pneumonitis that required steroids or current pneumonitis * Any of the following: * Pregnant persons * Nursing persons * Persons of childbearing potential who are unwilling to employ adequate contraception * Any autoimmune disease such as inflammatory bowel disease, including but not limited to: * Ulcerative colitis * Crohn's disease * Rheumatoid arthritis * Systemic sclerosis * Systemic lupus erythematosus * Autoimmune hepatitis * Other autoimmune disease not listed above * NOTE: Subjects with autoimmune thyroid disease and diabetes mellitus type I will be allowed * Uncontrolled intercurrent illness including, but not limited to, * Ongoing or active infection * Symptomatic congestive heart failure * Unstable angina pectoris * Cardiac arrhythmia, or * Psychiatric illness/social situations that would limit compliance with study requirements * Other active malignancy =\< 6 months prior to registration * EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix or prostate cancer confined to prostate gland with Gleason score \< 6 or prostate-specific antigen (PSA) \< 1 * NOTE: If there is a history of prior malignancy, they must not be receiving other treatment for their cancer; ongoing adjuvant hormonal treatment for breast cancer is allowed * Prior known allergic reaction to pembrolizumab or its excipients * Untreated brain metastasis * Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy * Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm * Received any live vaccine =\< 30 days prior to registration * Any of the following conditions =\< 6 weeks prior to registration: * Cerebrovascular accident (CVA) * Admission for unstable angina * Cardiac angioplasty or stenting or coronary artery bypass graft surgery * Pulmonary embolism or untreated deep venous thrombosis (DVT) * Arterial thrombosis * Class III or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival Rate | At 6 months | Defined as the percentage of evaluable patients who are alive at 6 months. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Adverse Events Graded Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | 2.3 years | The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine adverse event patterns. This data is reported in the adverse events section of this report. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Number of Patients With Locoregional Recurrence and Locoregional Progression in the Thyroid Bed or Regional Lymph Nodes | 2.3 years | Will be summarized using descriptive statistics. |
| Numbers of Patients With Distant Metastasis | Up to 5 years | Will be summarized using descriptive statistics. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Cohort B (Pembrolizumab, Chemoradiation) Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 17 courses after chemoradiation if no residual disease is found or for up to 35 courses after chemoradiation if residual disease is found. After 3 days, patients also receive docetaxel IV over 1 hour Q1W and doxorubicin hydrochloride IV Q1W, and undergo IMRT once daily 5 days per week for 6.5 weeks in the absence of disease progression or unacceptable toxicity.\>
\> Docetaxel: Given IV\>
\> Doxorubicin Hydrochloride: Given IV\>
\> Intensity-Modulated Radiation Therapy: Undergo IMRT\>
\> Laboratory Biomarker Analysis: Correlative studies\>
\> Pembrolizumab: Given IV | 3 |
| Total | 3 |
Baseline characteristics
| Characteristic | Cohort B (Pembrolizumab, Chemoradiation) |
|---|---|
| Age, Continuous | 56 years |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 3 Participants |
| Sex: Female, Male Female | 2 Participants |
| Sex: Female, Male Male | 1 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 3 / 3 | 0 / 0 |
| other Total, other adverse events | 3 / 3 | 0 / 0 |
| serious Total, serious adverse events | 3 / 3 | 0 / 0 |
Outcome results
Primary
Overall Survival Rate
Defined as the percentage of evaluable patients who are alive at 6 months.
Time frame: At 6 months
Population: All patients
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cohort B (Pembrolizumab, Chemoradiation) | Overall Survival Rate | 0 percentage of participants alive |
Secondary
Incidence of Adverse Events Graded Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0
The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine adverse event patterns. This data is reported in the adverse events section of this report.
Time frame: 2.3 years
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort B (Pembrolizumab, Chemoradiation) | Incidence of Adverse Events Graded Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | 3 Participants |
Other Pre-specified
Number of Patients With Locoregional Recurrence and Locoregional Progression in the Thyroid Bed or Regional Lymph Nodes
Will be summarized using descriptive statistics.
Time frame: 2.3 years
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort B (Pembrolizumab, Chemoradiation) | Number of Patients With Locoregional Recurrence and Locoregional Progression in the Thyroid Bed or Regional Lymph Nodes | 0 Participants |
Other Pre-specified
Numbers of Patients With Distant Metastasis
Will be summarized using descriptive statistics.
Time frame: Up to 5 years